Menu
This company is building on and commercialising a discovery by MD Andersen Cancer Centre, Texas, which significantly improves outcomes from established cancer treatments.
The business has formed a pharma industry partnership around which mixed finance has formed amounting to £12.5m to carry the project forward into Clinical studies.
Ruffena worked with the client to develop a valuation, financial model and investor pitch. We targeted and arranged interviews with venture funds in two continents. Throughout the process the business met its projected milestones.
Funding has secured a financial runway to the next significant milestones. The investment material developed was used extensively and helped to attract the industrial partner and underpins the approach to further finance.
This company is building on and commercialising a discovery by MD Andersen Cancer Centre, Texas, which significantly improves outcomes from established cancer treatments.
The business has formed a pharma industry partnership around which mixed finance has formed amounting to £12.5m to carry the project forward into Clinical studies.
Ruffena worked with the client to develop a valuation, financial model and investor pitch. We targeted and arranged interviews with venture funds in two continents. Throughout the process the business met its projected milestones.
Funding has secured a financial runway to the next significant milestones. The investment material developed was used extensively and helped to attract the industrial partner and underpins the approach to further finance.